Jump Financial LLC Takes $1.56 Million Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Jump Financial LLC made a new investment of approximately $1.56 million in ANI Pharmaceuticals, acquiring 23,221 shares during the first quarter.
• Analysts have a generally positive outlook for ANI Pharmaceuticals, with several firms, including HC Wainwright and Guggenheim, maintaining buy ratings and increasing their target prices for the stock.
• ANI Pharmaceuticals reported earnings of $1.80 per share for the last quarter, exceeding analyst expectations, and showed a year-over-year revenue increase of 53.2%.

Jump Financial LLC acquired a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,221 shares of the specialty pharmaceutical company's stock, valued at approximately $1,555,000. Jump Financial LLC owned 0.11% of ANI Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Millennium Management LLC boosted its position in shares of ANI Pharmaceuticals by 89.3% during the 4th quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock valued at $55,437,000 after purchasing an additional 473,097 shares in the last quarter. Aberdeen Group plc raised its position in shares of ANI Pharmaceuticals by 76.1% during the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock worth $28,059,000 after purchasing an additional 181,134 shares during the period. Deep Track Capital LP lifted its holdings in shares of ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the last quarter. Global Alpha Capital Management Ltd. boosted its position in shares of ANI Pharmaceuticals by 17.8% in the 1st quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock valued at $49,248,000 after purchasing an additional 111,040 shares during the period. Finally, GAMMA Investing LLC increased its stake in ANI Pharmaceuticals by 17,558.4% in the 1st quarter. GAMMA Investing LLC now owns 95,002 shares of the specialty pharmaceutical company's stock worth $6,360,000 after purchasing an additional 94,464 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $90.44, for a total transaction of $4,792,234.72. Following the completion of the sale, the chief operating officer owned 431,920 shares of the company's stock, valued at approximately $39,062,844.80. The trade was a 10.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Antonio R. Pera sold 5,421 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $89.73, for a total value of $486,426.33. Following the completion of the sale, the director owned 29,952 shares of the company's stock, valued at $2,687,592.96. This represents a 15.33% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 405,538 shares of company stock worth $35,690,131. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $0.29 on Wednesday, reaching $94.39. The stock had a trading volume of 61,389 shares, compared to its average volume of 372,272. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54. The business's 50-day moving average price is $74.48 and its two-hundred day moving average price is $67.55. The stock has a market cap of $2.05 billion, a P/E ratio of -122.41 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $95.60.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same quarter last year, the firm posted $1.02 EPS. The company's revenue was up 53.2% on a year-over-year basis. On average, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Zacks Research upgraded shares of ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 21st. Truist Financial raised their target price on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research report on Monday, August 11th. Guggenheim reissued a "buy" rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $93.00 target price (up previously from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $84.75.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.